Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ResMed (RMD)

ResMed adds AbbVie executive Nicole Mowad-Nassar to board; Richard Sulpizio to retire

Neutral Impact 2 of 5 leadership Written later

ResMed elected Nicole Mowad-Nassar, senior vice president at AbbVie, to its board effective August 15, 2025. Director Richard Sulpizio, who has served since 2005, will not stand for reelection and will retire at the November 19, 2025 annual meeting. The filing does not describe any financial effect of these board changes.

Key points

  • Nicole Mowad-Nassar elected August 15, 2025, with a term running to the 2025 annual meeting on November 19, 2025; she joins the Compensation and Leadership Development Committee
  • Mowad-Nassar is SVP at AbbVie and president of specialty and U.S. therapeutics operations, a role held since July 2023
  • Richard Sulpizio, a director since 2005, will retire at the 2025 annual meeting; the filing says his decision is not due to any disagreement with ResMed
  • Non-executive director cash retainer increases to $75,000 for fiscal year 2026, as approved by the board in May 2025

The filing

CompanyResMed (RMD)
Form8-K, current report
Filed with the SECAug 18, 2025, 4:20 PM ET
Accession number0001193125-25-182695

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:30 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 18, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.